Clareo Health | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–45
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participants with Body Mass Index (BMI) 18-34 kilograms per meter square (kg/m\^2), inclusive
Male participants who are willing to use barrier contraception for the duration of the study and for 3 months following the end of treatment
Female participants who are of non-child bearing potential
Female participants who are of child bearing potential utilizing two effective methods of contraception for the duration of the study and for 3 months following the end of treatment
You may not be if
Evidence of clinically significant disease or disorder (for example, renal, cardiac, bronchopulmonary)
Any other condition or disease which would place the participant at undue risk, or interfere with the assessment, or with the ability of the participant to complete the study
Clinically significant orthostatic hypotension present at screening or history of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness.
Participants with abnormal electrocardiogram (ECG), bradycardia or mean QTc at screening
Positive result for Hepatitis B, Hepatitis C, human immunodeficiency virus (HIV) 1 or 2 at screening
Renal impairment
Transplant recipients
A known clinically relevant history of allergy or hypersensitivity
Any clinically relevant abnormal laboratory test results
A clinically relevant history of abuse of alcohol or other drugs of abuse
Any major illness within 30 days prior to the screening examination
Smoking of more than 10 cigarettes a day or an equivalent amount of tobacco in the form of cigars or pipe
Participation in a clinical study with an investigational drug within 3 months prior to Day 1
Donation/loss of more than 500 milliliters (mL) of blood within 3 months prior to Day 1
Positive pregnancy test at screening or Day -1 and lactating women
